Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
J Neurovirol ; 27(5): 797-801, 2021 10.
Article in English | MEDLINE | ID: covidwho-1432669


Guillain-Barré syndrome (GBS) is an ascending demyelinating polyneuropathy often associated with recent infection. Miller Fisher syndrome represents a variant with predominant facial and cranial nerve involvement, although Miller Fisher and Guillain-Barré overlap syndromes can occur. Guillain-Barré spectrum syndromes have been thought to be rare among solid organ transplant recipients. We describe an immunocompromised patient with a liver transplant who presented with ophthalmoplegia and bulbar deficits. His symptoms rapidly progressed to a state of descending paralysis involving the diaphragm; he then developed acute respiratory failure and eventually developed quadriparesis. Electromyography and a nerve conduction study demonstrated a severe sensorimotor axonal polyneuropathy consistent with Miller Fisher variant Guillain-Barré syndrome. Despite several negative nasopharyngeal swabs for COVID-19 polymerase chain reaction, a serology for SARS-CoV-2 IgG was positive. He was diagnosed with Miller Fisher-Guillain-Barré overlap syndrome with rapid recovery following treatment with plasma exchange. Although Guillain-Barré is a rare complication in solid organ transplant recipients, this case highlights the importance of rapid diagnosis and treatment of neurologic complications in transplant patients. Furthermore, it demonstrates a possible case of neurological complications from COVID-19 infection.

COVID-19/complications , Guillain-Barre Syndrome/immunology , Guillain-Barre Syndrome/virology , Miller Fisher Syndrome/immunology , Miller Fisher Syndrome/virology , Guillain-Barre Syndrome/therapy , Humans , Immunocompromised Host , Liver Transplantation , Male , Middle Aged , Miller Fisher Syndrome/therapy , Plasmapheresis , SARS-CoV-2 , Transplant Recipients
J Neurovirol ; 26(4): 605-606, 2020 08.
Article in English | MEDLINE | ID: covidwho-593343


This case report describes the clinical characteristics of a 50-year-old woman that developed SARS-CoV-2 pneumonia and was admitted at the COVID-19 dedicated unit where she developed neurological symptoms 10 days after admission. After neurological examination, including a panel of blood cerebrospinal fluid biomarkers, a diagnosis of Miller Fisher syndrome (MFS) was hypothesized and intravenous immunoglobulin therapy (IVIG) was initiated. Fourteen days after the start of IVIG treatment, the patient has been discharged at home with the resolution of respiratory symptoms and only minor hyporeflexia at the lower limbs, without any side effect.

Coronavirus Infections/complications , Immunoglobulins, Intravenous/therapeutic use , Miller Fisher Syndrome/drug therapy , Miller Fisher Syndrome/virology , Pneumonia, Viral/complications , Betacoronavirus , COVID-19 , Female , Humans , Middle Aged , Pandemics , SARS-CoV-2